About Antares Pharma (NASDAQ:ATRS)
Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. The Company's subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injectors, Vision reusable needle-free injectors and disposable multi-use pen injectors. The Company operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies. The Company has developed OTREXUP (methotrexate) injection, which is a single dose, disposable auto injector.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
SymbolNASDAQ:ATRS
CUSIP03664210
Phone609-359-3020
Debt
Debt-to-Equity Ratio0.74%
Current Ratio3.53%
Quick Ratio2.94%
Price-To-Earnings
Trailing P/E Ratio-20.91
Forward P/E Ratio-32.86
P/E GrowthN/A
Sales & Book Value
Annual Sales$54.51 million
Price / Sales6.62
Cash FlowN/A
Price / CashN/A
Book Value$0.21 per share
Price / Book10.95
Profitability
EPS (Most Recent Fiscal Year)($0.11)
Net Income$-16,740,000.00
Net Margins-30.71%
Return on Equity-44.29%
Return on Assets-22.44%
Miscellaneous
Employees111
Outstanding Shares156,790,000
Antares Pharma (NASDAQ:ATRS) Frequently Asked Questions
What is Antares Pharma's stock symbol?
Antares Pharma trades on the NASDAQ under the ticker symbol "ATRS."
How were Antares Pharma's earnings last quarter?
Antares Pharma Inc (NASDAQ:ATRS) announced its earnings results on Tuesday, March, 13th. The specialty pharmaceutical company reported ($0.02) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.03) by $0.01. The specialty pharmaceutical company had revenue of $14 million for the quarter, compared to analysts' expectations of $15.44 million. Antares Pharma had a negative return on equity of 44.29% and a negative net margin of 30.71%. The company's revenue was down 1.4% on a year-over-year basis. View Antares Pharma's Earnings History.
What price target have analysts set for ATRS?
3 analysts have issued 12 month target prices for Antares Pharma's shares. Their forecasts range from $3.00 to $5.00. On average, they anticipate Antares Pharma's stock price to reach $4.00 in the next year. View Analyst Ratings for Antares Pharma.
Who are some of Antares Pharma's key competitors?
Some companies that are related to Antares Pharma include Cerus (CERS), Anika Therapeutics (ANIK), Tactile Systems Technology (TCMD), SurModics (SRDX), Accuray (ARAY), Inovio Pharmaceuticals (INO), Utah Medical Products (UTMD), Endologix (ELGX), GenMark Diagnostics (GNMK), Tandem Diabetes Care (TNDM), Pulse Biosciences (PLSE), Orthopediatrics (KIDS), T2 Biosystems (TTOO), Cytosorbents (CTSO), Nuvectra (NVTR), SeaSpine (SPNE), IRadimed (IRMD) and Restoration Robotics (HAIR).
Who are Antares Pharma's key executives?
Antares Pharma's management team includes the folowing people:
- Leonard S. Jacob M.D., Ph.D., Independent Chairman of the Board (Age 68)
- Robert F. Apple CPA, President, Chief Executive Officer, Director (Age 51)
- Fred M. Powell CPA, Chief Financial Officer, Senior Vice President, Principal Financial Officer and Principal Accounting Officer (Age 56)
- Peter J. Graham, Senior Vice President, General Counsel, Human Resources, Chief Compliance Officer (Age 50)
- Thomas J. Garrity, Independent Director (Age 68)
- Jacques Gonella Ph.D., Independent Director (Age 75)
- Anton G. Gueth, Independent Director (Age 60)
- Robert P. Roche Jr., Independent Director (Age 61)
- Marvin S. Samson, Independent Director (Age 75)
Has Antares Pharma been receiving favorable news coverage?
News headlines about ATRS stock have trended somewhat negative on Monday, according to Accern Sentiment Analysis. The research group identifies positive and negative media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Antares Pharma earned a media sentiment score of -0.02 on Accern's scale. They also gave news stories about the specialty pharmaceutical company an impact score of 46.14 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
How do I buy shares of Antares Pharma?
Shares of ATRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Antares Pharma's stock price today?
One share of ATRS stock can currently be purchased for approximately $2.30.
How big of a company is Antares Pharma?
Antares Pharma has a market capitalization of $360.61 million and generates $54.51 million in revenue each year. The specialty pharmaceutical company earns $-16,740,000.00 in net income (profit) each year or ($0.11) on an earnings per share basis. Antares Pharma employs 111 workers across the globe.
How can I contact Antares Pharma?
Antares Pharma's mailing address is 100 PRINCETON SOUTH SUITE 300, EWING NJ, 08628. The specialty pharmaceutical company can be reached via phone at 609-359-3020 or via email at [email protected]
MarketBeat Community Rating for Antares Pharma (ATRS)
MarketBeat's community ratings are surveys of what our community members think about Antares Pharma and other stocks. Vote "Outperform" if you believe ATRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Antares Pharma (NASDAQ:ATRS) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for Antares Pharma in the last 12 months. Their average twelve-month price target is $4.00, suggesting that the stock has a possible upside of 73.91%. The high price target for ATRS is $5.00 and the low price target for ATRS is $3.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.25 | 3.25 | 3.25 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
1 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
1 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
1 Strong Buy Rating(s) |
| Consensus Price Target: | $4.00 | $4.0750 | $3.95 | $3.95 |
| Price Target Upside: | 73.91% upside | 53.77% upside | 138.67% upside | 81.19% upside |
Antares Pharma (NASDAQ:ATRS) Consensus Price Target History
Antares Pharma (NASDAQ:ATRS) Analyst Ratings History
Show:
(Data available from 4/23/2016 forward)
Antares Pharma (NASDAQ:ATRS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Antares Pharma (NASDAQ ATRS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 11.60%
Institutional Ownership Percentage: 35.34%
Antares Pharma (NASDAQ ATRS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 10/9/2017 | Leonard S Jacob | Director | Sell | 230,000 | $4.05 | $931,500.00 | |  |
| 10/3/2017 | Thomas J Garrity | Director | Sell | 30,000 | $3.50 | $105,000.00 | | |
| 6/9/2017 | Fred M Powell | Insider | Buy | 130,000 | $2.79 | $362,700.00 | 331,434 | |
| 4/5/2017 | Robert F Apple | CEO | Sell | 40,000 | $3.00 | $120,000.00 | 927,002 | |
| 4/4/2017 | Leonard S Jacob | Director | Sell | 41,762 | $2.89 | $120,692.18 | 238,885 | |
| 4/4/2017 | Robert F Apple | CEO | Sell | 37,000 | $3.00 | $111,000.00 | 927,002 | |
| 4/3/2017 | Leonard S Jacob | Director | Sell | 20,000 | $2.88 | $57,600.00 | 238,885 | |
| 3/31/2017 | Thomas J Garrity | Director | Sell | 30,000 | $2.91 | $87,300.00 | 190,213 | |
| 12/9/2016 | Fred M Powell | Insider | Buy | 100,000 | $2.03 | $203,000.00 | 100,000 | |
| 3/21/2016 | Peter J Graham | SVP | Buy | 20,000 | $0.77 | $15,400.00 | 20,000 | |
| 3/18/2016 | James E Fickenscher | CFO | Buy | 135,000 | $0.72 | $97,200.00 | 270,216 | |
| 3/18/2016 | Leonard S Jacob | Director | Buy | 50,000 | $0.72 | $36,000.00 | 218,885 | |
| 3/18/2016 | Robert F Apple | CEO | Buy | 60,000 | $0.72 | $43,200.00 | 517,164 | |
| 9/30/2015 | James E Flynn | Major Shareholder | Sell | 249,998 | $1.69 | $422,496.62 | | |
| 9/29/2015 | James E Flynn | Major Shareholder | Sell | 225,048 | $1.82 | $409,587.36 | | |
| 9/28/2015 | James E Flynn | Major Shareholder | Sell | 1,353,483 | $1.81 | $2,449,804.23 | | |
| 8/24/2015 | Robert P Roche Jr | Director | Buy | 5,000 | $1.77 | $8,850.00 | 38,172 | |
| 8/13/2015 | Robert P Roche Jr | Director | Buy | 5,000 | $1.94 | $9,700.00 | | |
| 7/20/2015 | James E Flynn | Insider | Sell | 231,793 | $2.17 | $502,990.81 | | |
| 7/8/2015 | James E Flynn | Major Shareholder | Sell | 444,341 | $2.05 | $910,899.05 | | |
| 7/7/2015 | James E Flynn | Major Shareholder | Sell | 198,651 | $2.09 | $415,180.59 | | |
| 7/6/2015 | James E Flynn | Major Shareholder | Sell | 191,513 | $2.12 | $406,007.56 | | |
| 7/1/2015 | James E Flynn | Insider | Sell | 713,222 | $2.09 | $1,490,633.98 | | |
| 6/30/2015 | James E Flynn | Major Shareholder | Sell | 608,691 | $2.08 | $1,266,077.28 | | |
| 6/29/2015 | James E Flynn | Major Shareholder | Sell | 60,695 | $2.18 | $132,315.10 | | |
| 6/26/2015 | James E Flynn | Insider | Sell | 756,852 | $2.27 | $1,718,054.04 | | |
| 6/23/2015 | James E Flynn | Insider | Sell | 499,895 | $2.39 | $1,194,749.05 | | |
| 6/18/2015 | James E Flynn | Insider | Sell | 478,366 | $2.44 | $1,167,213.04 | | |
| 6/15/2015 | James E Flynn | Insider | Sell | 748,030 | $2.44 | $1,825,193.20 | | |
| 3/23/2015 | Leonard S Jacob | Director | Sell | 23,500 | $2.68 | $62,980.00 | | |
| 9/10/2014 | Eamonn P Hobbs | CEO | Buy | 9,000 | $2.20 | $19,800.00 | | |
| 8/13/2014 | Robert P Roche Jr | Director | Buy | 5,000 | $1.96 | $9,800.00 | | |
| 8/11/2014 | Marvin Samson | Director | Buy | 25,000 | $2.00 | $50,000.00 | | |
| 12/9/2013 | Paul Wotton | CEO | Sell | 64,100 | $4.00 | $256,400.00 | 708,734 | |
| 10/14/2013 | Robert Apple | CFO | Sell | 22,000 | $5.05 | $111,100.00 | 368,918 | |
| 9/3/2013 | Anton Gueth | Director | Sell | 25,000 | $4.42 | $110,500.00 | 245,976 | |
| 9/3/2013 | Paul Wotton | CEO | Sell | 35,000 | $4.41 | $154,350.00 | 708,734 | |
| 8/1/2013 | Anton Gueth | Director | Sell | 25,000 | $4.41 | $110,250.00 | | |
| 8/1/2013 | Paul K Wotton | CEO | Sell | 35,000 | $4.42 | $154,700.00 | | |
| 7/1/2013 | Anton Gueth | Director | Sell | 25,000 | $4.15 | $103,750.00 | | |
| 7/1/2013 | Paul K Wotton | CEO | Sell | 35,000 | $4.14 | $144,900.00 | | |
| 6/25/2013 | Eamonn P Hobbs | Director | Sell | 23,500 | $4.19 | $98,465.00 | | |
| 6/4/2013 | Robert F Apple | CFO | Sell | 115,000 | $4.02 | $462,300.00 | | |
| 6/3/2013 | Anton Gueth | Director | Sell | 25,000 | $4.01 | $100,250.00 | | |
| 6/3/2013 | Kaushik J Dave | EVP | Sell | 48,000 | $4.01 | $192,480.00 | | |
| 6/3/2013 | Paul K Wotton | CEO | Sell | 125,000 | $4.01 | $501,250.00 | | |
| 5/31/2013 | Thomas J Garrity | Director | Sell | 13,000 | $4.08 | $53,040.00 | | |
| 5/17/2013 | Leonard S Jacob | Director | Sell | 17,000 | $4.00 | $68,000.00 | | |
| 11/16/2012 | Leonard S Jacob | Director | Buy | 10,000 | $3.44 | $34,400.00 | | |
(Data available from 1/1/2013 forward)
Antares Pharma (NASDAQ ATRS) News Headlines
| Source: |
|
Antares Pharma (NASDAQ:ATRS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Antares Pharma (NASDAQ:ATRS) Income Statement, Balance Sheet and Cash Flow Statement
Antares Pharma (NASDAQ ATRS) Stock Chart for Monday, April, 23, 2018
Loading chart…
